These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. Di Lorenzo G; Ferro M; Buonerba C BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289 [TBL] [Abstract][Full Text] [Related]
11. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902 [TBL] [Abstract][Full Text] [Related]
12. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125 [TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy: sipuleucel-T and beyond. Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608 [TBL] [Abstract][Full Text] [Related]
14. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643 [TBL] [Abstract][Full Text] [Related]
15. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218 [No Abstract] [Full Text] [Related]
16. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Garcia JA; Dreicer R Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467 [TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Wei XX; Fong L; Small EJ Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270 [TBL] [Abstract][Full Text] [Related]
18. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Cheever MA; Higano CS Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]
20. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]